Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2003 3
2005 1
2007 1
2009 2
2011 1
2019 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Twelve-month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed-loop therapy outcomes versus conventional therapy in adults with type 1 diabetes.
Edd SN, Castañeda J, Choudhary P, Kolassa R, Keuthage W, Kroeger J, Thivolet C, Evans M, Ré R, Cellot J, de Portu S, Vorrink L, Shin J, van den Heuvel T, Cohen O; ADAPT study Group. Edd SN, et al. Diabetes Obes Metab. 2023 Nov;25(11):3212-3222. doi: 10.1111/dom.15217. Epub 2023 Aug 8. Diabetes Obes Metab. 2023. PMID: 37551542 Clinical Trial.
Multicentre, randomised, controlled study of the impact of continuous sub-cutaneous glucose monitoring (GlucoDay) on glycaemic control in type 1 and type 2 diabetes patients.
Cosson E, Hamo-Tchatchouang E, Dufaitre-Patouraux L, Attali JR, Pariès J, Schaepelynck-Bélicar P. Cosson E, et al. Among authors: schaepelynck belicar p. Diabetes Metab. 2009 Sep;35(4):312-8. doi: 10.1016/j.diabet.2009.02.006. Epub 2009 Jun 26. Diabetes Metab. 2009. PMID: 19560388 Clinical Trial.
Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.
Bosi E, Choudhary P, de Valk HW, Lablanche S, Castañeda J, de Portu S, Da Silva J, Ré R, Vorrink-de Groot L, Shin J, Kaufman FR, Cohen O; SMILE Study Group. Bosi E, et al. Lancet Diabetes Endocrinol. 2019 Jun;7(6):462-472. doi: 10.1016/S2213-8587(19)30150-0. Epub 2019 Apr 29. Lancet Diabetes Endocrinol. 2019. PMID: 31047902 Clinical Trial.
The Diabeo software enabling individualized insulin dose adjustments combined with telemedicine support improves HbA1c in poorly controlled type 1 diabetic patients: a 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 Study).
Charpentier G, Benhamou PY, Dardari D, Clergeot A, Franc S, Schaepelynck-Belicar P, Catargi B, Melki V, Chaillous L, Farret A, Bosson JL, Penfornis A; TeleDiab Study Group. Charpentier G, et al. Among authors: schaepelynck belicar p. Diabetes Care. 2011 Mar;34(3):533-9. doi: 10.2337/dc10-1259. Epub 2011 Jan 25. Diabetes Care. 2011. PMID: 21266648 Free PMC article. Clinical Trial.
A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion.
Liebl A, Hoogma R, Renard E, Geelhoed-Duijvestijn PH, Klein E, Diglas J, Kessler L, Melki V, Diem P, Brun JM, Schaepelynck-Bélicar P, Frei T; European DiaPort Study Group. Liebl A, et al. Among authors: schaepelynck belicar p. Diabetes Obes Metab. 2009 Nov;11(11):1001-8. doi: 10.1111/j.1463-1326.2009.01059.x. Epub 2009 Sep 9. Diabetes Obes Metab. 2009. PMID: 19740082 Clinical Trial.
11 results